Behavioral Medicine in Multiple Sclerosis:
Exploring Changes in Emotional and Physical Functioning

Sullivan1, A.B., Greenberg1, B., Fan2, Y., Carriere1, L., & Sacco1, M.

Mellen Center for Multiple Sclerosis Treatment & Research1, Department of Quantitative Health Sciences2

Abstract

Patients (n = 505) who were diagnosed with multiple sclerosis (MS) and seen by health psychology at the Mellen Center for Multiple Sclerosis at the Cleveland Clinic from 2010-2015 were retrospectively included in this study. Paired t-tests, multivariable linear regression, and visual inspection of box plots with confidence intervals were used to evaluate if participation in at least 3 sessions with health psychology resulted in improvements in patients’ emotional well being. Results from the analyses revealed that although participation in health psychology helped reduce anxiety and depression, this did not hold true for generalized anxiety and disability due to pain. Additionally, participants’ course of MS was non-significant as a predictor of their improvement in depression, anxiety, quality of life, or disability from pain.

Method

Data Pull

Data for this study was retrospectively gathered from electronic medical records kept by the Cleveland Clinic as part of the Knowledge Program (Katzman, et al., 2011).

Participants

Patients who were diagnosed with MS, were at least 18 years old, and who were seen by Behavioral Medicine (BM) at the Mellen Center for Multiple Sclerosis between 2010 and 2015 were included in the initial data pull. This resulted in a total of 505 eligible patients. Descriptive statistics for included measures are listed below grouped by participants who had fewer than 3 sessions or 3 or greater sessions of psychotherapy as an approximation of patients being engaged in therapy.

Background

MS is a disease in which approximately 50% of the individuals will experience a depression and 40% an anxiety at some point during their disease, which is four times as high as in any other neurologic condition. (1, 2). The completed suicide rate is 7.5 times as high as the general population (2). In addition, anxiety is reported more often than depression in neurology clinics and has been linked to the presence of exacerbations and pseudosuicidal behaviors and left untreated, can worsen MS symptoms by increasing functional impairment, decrease adherence to treatment, worsen quality of life and may lead to suicidal ideation and completion (3). Mind body interventions such as exercise, relaxation, stress management and cognitive behavioral therapy have been helpful in managing these symptoms and in the prevention of brain lesions (4). This has highlighted the benefits of psychotherapy pre-treatment or at months following and of treatment; however, a report of patients’ change in emotional and physical functioning over time in patients who chose to receive health psychology services versus those who do not, is missing. In addition, no study has examined if the disease course has any significance in the outcome of behavioral medicine interventions.

Objectives

1) Identify how emotional and physical functioning changes over time in patients who choose to receive health psychology (HP) services at Mellen Center versus those who do not
2) Determine if the MS disease course has any significant impact on the outcomes

Results

A series of paired t-tests were conducted to compare participants’ first and last recorded values for the EQ5D, PHQ9, GAD7, and PDI from their completed HP sessions. Only patients who received at least 3 sessions with HP were included in the analysis to ensure participants were actively involved in treatment.

Patients with MS who participated in at least 3 sessions of HP experienced a statistically significant reduction in both anxiety and depression between their first and last sessions. On average, their depression scores on the PHQ9 decreased by 1.84, while their anxiety scores on the GAD7 decreased by 1.12. However, there was considerable interpersonal variability in the amount that scores decreased, as evidenced by the high standard deviation for each measure. Despite the statistically significant reductions in anxiety and depression, a similar trend was not found in quality of life measured by the EQ5D or perceived disability due to pain measured by the PDI. These findings suggest that participation in HP is beneficial for patients’ emotional well being, but may have less of a direct effect on other measures of functioning.

While there was a significant difference between primary progressive MS and relapsing remitting MS on the GAD7, and a difference between secondary progressive MS with relapses and relapsing remitting MS on the PDI, these results may be likely due to chance rather than a true finding as they were not observed consistently between courses of MS for each outcome measure.

Examination of first to last differences on the PHQ9 and GAD7 revealed that participation in additional sessions, up to a point, resulted in improved reduction in depression and anxiety. However, further sessions (after approximately 10 total sessions) did not have this effect. This may indicate that individuals with MS who receive further sessions may have more persistent emotional distress requiring management.

Discussion

MS is a disease in which approximately 50% of the individuals will experience a depression and 40% an anxiety at some point during their disease, which is four times as high as in any other neurologic condition. (1, 2). The completed suicide rate is 7.5 times as high as the general population (2). In addition, anxiety is reported more often than depression in neurology clinics and has been linked to the presence of exacerbations and pseudosuicidal behaviors and left untreated, can worsen MS symptoms by increasing functional impairment, decrease adherence to treatment, worsen quality of life and may lead to suicidal ideation and completion (3). Mind body interventions such as exercise, relaxation, stress management and cognitive behavioral therapy have been helpful in managing these symptoms and in the prevention of brain lesions (4). This has highlighted the benefits of psychotherapy pre-treatment or at months following and of treatment; however, a report of patients’ change in emotional and physical functioning over time in patients who chose to receive health psychology services versus those who do not, is missing. In addition, no study has examined if the disease course has any significance in the outcome of behavioral medicine interventions.

Objectives

1) Identify how emotional and physical functioning changes over time in patients who choose to receive health psychology (HP) services at Mellen Center versus those who do not
2) Determine if the MS disease course has any significant impact on the outcomes

Results

A series of paired t-tests were conducted to compare participants’ first and last recorded values for the EQ5D, PHQ9, GAD7, and PDI from their completed HP sessions. Only patients who received at least 3 sessions with HP were included in the analysis to ensure participants were actively involved in treatment.

Patients with MS who participated in at least 3 sessions of HP experienced a statistically significant reduction in both anxiety and depression between their first and last sessions. On average, their depression scores on the PHQ9 decreased by 1.84, while their anxiety scores on the GAD7 decreased by 1.12. However, there was considerable interpersonal variability in the amount that scores decreased, as evidenced by the high standard deviation for each measure. Despite the statistically significant reductions in anxiety and depression, a similar trend was not found in quality of life measured by the EQ5D or perceived disability due to pain measured by the PDI. These findings suggest that participation in HP is beneficial for patients’ emotional well being, but may have less of a direct effect on other measures of functioning.

While there was a significant difference between primary progressive MS and relapsing remitting MS on the GAD7, and a difference between secondary progressive MS with relapses and relapsing remitting MS on the PDI, these results may be likely due to chance rather than a true finding as they were not observed consistently between courses of MS for each outcome measure.

Examination of first to last differences on the PHQ9 and GAD7 revealed that participation in additional sessions, up to a point, resulted in improved reduction in depression and anxiety. However, further sessions (after approximately 10 total sessions) did not have this effect. This may indicate that individuals with MS who receive further sessions may have more persistent emotional distress requiring management.

Discussion

MS is a disease in which approximately 50% of the individuals will experience a depression and 40% an anxiety at some point during their disease, which is four times as high as in any other neurologic condition. (1, 2). The completed suicide rate is 7.5 times as high as the general population (2). In addition, anxiety is reported more often than depression in neurology clinics and has been linked to the presence of exacerbations and pseudosuicidal behaviors and left untreated, can worsen MS symptoms by increasing functional impairment, decrease adherence to treatment, worsen quality of life and may lead to suicidal ideation and completion (3). Mind body interventions such as exercise, relaxation, stress management and cognitive behavioral therapy have been helpful in managing these symptoms and in the prevention of brain lesions (4). This has highlighted the benefits of psychotherapy pre-treatment or at months following and of treatment; however, a report of patients’ change in emotional and physical functioning over time in patients who chose to receive health psychology services versus those who do not, is missing. In addition, no study has examined if the disease course has any significance in the outcome of behavioral medicine interventions.